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Neuroblastoma, which derives from neural crest, is the most common extracranial solid cancer in childhood. The tumors express
the norepinephrine (NE) transporters on their cell membrane and take in metaiodobenzylguanidine (MIBG) via a NE transporter.
Since iodine-131 (I-131) MIBG therapy was firstly reported, many trails of MIBG therapy in patients with neuroblastoma were
performed. Th ugh monotherapy with a low dose of I-131 MIBG could achieve high-probability pain reduction, the objective
response was poor. In contrast, more than 12 mCi/kg I-131MIBG administrations with or without hematopoietic cell transplantation
(HCT) obtain relatively good responses in patients with refractory or relapsed neuroblastoma. The combination therapy with I-131
MIBG and other modalities such as nonmyeloablative chemotherapy and myeloablative chemotherapy with HCT improved the
therapeutic response in patients with refractory or relapsed neuroblastoma. In addition, I-131 MIBG therapy incorporated in the
induction therapy was proved to be feasible in patients with newly diagnosed neuroblastoma. To expand more the use of MIBG
therapy for neuroblastoma, further studies will be needed especially in the use at an earlier stage from diagnosis, in the use with
other radionuclide formations of MIBG, and in combined use with other therapeutic agents.
1. Introduction
Neuroblastoma derives from neural-crest tissues and arises
mostly from adrenal medulla or paraspinal ganglia. Th
tumor is the most common extracranial solid cancer in
childhood. The annual incidence is 10.2 cases per million
children under 15 years of age [1]. More than one-third of
the patients are diagnosed younger than one-year-old and the
median age at diagnosis is 17 months [2]. More than half of
patients have metastases at diagnosis. Main metastatic sites
are regional lymph nodes, liver, bone, and bone marrow [3].
Age, stage, and MYCN status are considered as consensus
determinants of prognosis. Age greater than 12 or 18 months
at diagnosis and patients with an advanced primary lesion or
metastases and patients with MYCN amplification have worse
outcomes [2–4]. Five-year survival rates of neuroblastoma
have remained approximately over 80% for infants and
improved for older children from approximately 40% before
1985 to 65% in around 2000 [5]. Nevertheless, the prognosis of
high-risk patients with neuroblastoma remains poor in spite
of forcible multimodality therapies.
Since metaiodobenzylguanidine (MIBG) was reported as
the adrenomedullary imaging agent in the early 1980s [6–8],
iodine-131 (I-131) MIBG and iodine-123 (I-123) MIBG were
widely used for detecting neuroendocrine tumors such as
pheochromocytoma, neuroblastoma, and medullary thyroid
cancer [9]. Because of emitting a beta ray with cytocidal
effects, I-131 MIBG was used with the aim of treatment for
neuroendocrine tumors from early afte the development
of MIBG. The first therapy with I-131 MIBG was applied
to pheochromocytoma patients [10]. In 1986, I-131 MIBG
therapy for neuroblastoma was reported for the first time [11].
Since then, many trials of I-131MIBG therapy in patients with
neuroblastoma have been done.
In this paper, we detail the development of I-131 MIBG
therapy in patients with neuroblastoma from the last decades
to the future.
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2. Mechanism of MIBG Uptake in
Neuroblastoma Cells
MIBG is an aralkylguanidine which is structurally similar
to the neurotransmitter norepinephrine (NE) and the gan-
glionic blocking drug guanethidine. Th uptake of MIBG
in neuroendocrine cells such as normal adrenomedullary
cells, neuroblastoma, and pheochromocytoma cells is similar
to the uptake of NE. MIBG enters neuroendocrine cells by
two pathways, a specifi uptake system (uptake-one) and a
nonspecifi uptake system. Uptake-one is an active process
via a NE transporter and is energy-requiring, sodium-
dependent, temperature-dependent, and low-capacity and
has a high affinity for MIBG. Th nonspecifi uptake is an
energy-independent passive diffusional mechanism [12–14].
In the clinical setting, uptake-one is the predominant uptake
system for MIBG [15, 16].
Once taken up into neuroendocrine cells, the majority of
MIBG remains within the cells. MIBG is not decomposed
by enzymes and is not bound to postsynaptic adrenergic
receptors [17]. Most neuroendocrine cells like pheochromo-
cytoma cells store MIBG in the neurosecretory granules.
By contrast, neuroblastoma cells typically have a paucity of
the neurosecretory granules and most MIBGs are stored
in the cytoplasm and mitochondria, rather than in the
neurosecretory granules [18, 19].
3. Indications and Contraindications
Th indications and contraindications of I-131MIBG therapy
for neuroblastoma are stated in the European Association of
Nuclear Medicine procedure guidelines [20]. Th indication
is Stage III or IV neuroblastoma with MIBG-avid lesions at
diagnostic I-123 MIBG or I-131 MIBG scintigraphy before
I-131 MIBG therapy. Because neuroblastoma arises from
neural-crest tissues, most lesions express NE transporters on
their cell surfaces and they take in and store radiolabeled
MIBG. If radiolabeled MIBG does not accumulate in the
lesions of neuroblastoma at pretherapy diagnostic study, I-
131MIBG therapy should not be performed. The aims of I-131
MIBG therapy are to achieve complete remission, to inhibit
tumor progression, and to alleviate symptoms from primary
or metastatic lesions. Absolute contraindications are renal
failure requiring dialysis and expected life less than 3 months
unless in case of refractory bone pain. Relative contraindica-
tions are provided as uncontrollable medical risk and urinary
incontinence by isolation and decreased renal function by
glomerular filtration rate (GFR) less than 30 mL/min.
In the guideline draft of I-131MIBG therapy for neurob-
lastoma from our country, life expectancy less than not 3
months but one month and decreased renal function by GFR
less than 30 mL/min are define as absolute contraindications
[21].
4. Toxicity of I-131 MIBG Therapy
Typical acute toxicities usually seen within two or three days
after I-131 MIBG administration are nausea and vomiting.
Ta ble 1: Acute toxicities in 40 patients with refractory or relapsed
neuroblastoma treated with I-131 MIBG at a mean dose of
10.5mCi/kg in our institution.
Toxicity
Grade (𝑛 = 40)
1 2 3 4
Anorexia 16 1 1 0
Nausea 12 1 1 0
Vomiting 2 2 0 0
Sialadenitis 2 7 0 0
Fatigue 3 1 0 0
Fever 2 1 0 0
Stomatitis 2 0 0 0
Toxicity is graded by the common terminology criteria for adverse events
version 4.0.
The e toxicities occur in approximately 10 to 20% of treated
patients. In a recent report, nausea and vomiting are observed
in 11%and 21% of 66 therapies treated with upfront I-131
MIBG therapy at a dose of 4.2 to 21.7mCi/kg for newly
diagnosed neuroblastoma [22]. Sialadenitis is seen with a
relatively high frequency. Five of 10patients (9 neuroblastoma
and 1 malignant pheochromocytoma) had bilateral parotid
swelling within 24 hours after 12 to 18 mCi/kg I-131 MIBG
injections [23]. Table 1 shows acute toxicities in 40 patients
with refractory or relapsed neuroblastoma treated with I-
131 MIBG at a mean dose of 10.5 mCi/kg in our institution.
Th ugh anorexia, nausea, and sialadenitis are seen with a
relatively high frequency, severe acute toxicities are rare. A
recent study investigated blood pressure (BP) changes within
48 hours after I-131 MIBG infusion [24]. BP-related adverse
events were seen in 4 of 50 patients. One of them had a hyper-
tensive encephalopathy. Another study reported that antihy-
pertensive drugs were required in 2.8% of 218 I-131 MIBG
administrations [25]. Th ugh clinically relevant BP changes
after I-131MIBG therapy is rare, BP changes should be mon-
itored at least within 48 hours after I-131MIBG injections.
Th most important toxicity is hematological with dose
dependency usually appears a few weeks after MIBG ther-
apy. Hematological toxicity is more noticeable in patients
with bone marrow metastases and received higher whole-
body radiation doses [26]. Hematopoietic cell transplantation
(HCT) was required in about one-third of patients treated
with 18 mCi/kg I-131 MIBG. In contrast, all patients treated
with less than 12mCi/kg of I-131 MIBG did not need HCT
[26–28]. To date, a dose of 12mCi/kg is considered as
the maximum tolerated dose of I-131 MIBG therapy with-
out HCT. Therefore, hematopoietic cell support should be
arranged when more than 12mCi/kg of I-131 MIBG was
administrated to the patient.
Venoocclusive liver disease (VOLD) is an important
early complication in patients received I-131 MIBG therapy
followed by myeloablative chemotherapy and HCT. Th new
approaches to neuroblastoma therapy (NANT) consortium
reported that 6 of 22 patients had VOLDs after the therapies
and an apparently high rate of VOLD was seen in the patients
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Figur e 1: A 13-year-old female with relapsed neuroblastoma. She received the fi st I-131 MIBG therapy at a dose of 5.0 mCi/kg. Multiple
accumulations are seen in a right retroperitoneal recurrence and multiple bone metastases ((a), arrows). Th second I-131MIBG therapy at
a dose of 4.9 mCi/kg was performed 4 months after the fi st therapy. A scintigram after the second therapy shows a disappearance of left
femoral uptake and decreasing uptakes in other lesions especially in a right retroperitoneum recurrence and a left humeral bone metastasis
(b). Th ugh the objective response at the firs therapy was stable by the response evaluation criteria in solid tumors, she became free of pain
in the lower extremity after the fi st therapy. Unfortunately, she died of progressive disease 14 months after the fi st I-131MIBG therapy.
with a low GFR [29]. In contrast, no VOLD was seen in
patients receiving double infusions of high-dose I-131MIBG
without chemotherapy [30]. The decreased clearance of the
chemotherapeutic agents was considered a major cause of
VOLD.
Hypothyroidism is a major late side effect, despite the
use of potassium iodine for the thyroid blockage. A Dutch
group investigated the late side effect on the thyroid gland
after I-131 MIBG therapy [31]. At a median follow-up time
of 1.4 years aft r I-131 MIBG therapy, 5 of 16 survivors had
TSH elevations. After a median follow-up time of 15.5years,
8 of the 16 survivors developed hypothyroidism needed with
thyroxin. In addition, papillary thyroid cancers were found in
2 of 9 survivors with thyroid nodules. Despite the protection
with potassium iodine, only 3 of 16 survivors maintained
normal thyroid function without any thyroid nodules. Th
incidence of thyroid disorders is high and increases as time
advances. Papillary thyroid cancers may occur with a rather
high frequency.
Second malignancies without thyroid cancers arise in less
than 5%. In a report from Italy, 2 leukemia, one angioma-
toid fi rous histiocytoma, one schwannoma, and one rhab-
domyosarcoma occurred in 119 patients with neuroblastoma
after I-131 MIBG therapy [32]. Th University of California,
San Francisco (UCSF) group described that leukemia was
observed in 3 of 95 patients with refractory neuroblastoma at
7, 11,and 12 months after I-131therapy [33]. It was difficult to
clarify the main factor of the second malignancies, because
all patients received several intensive therapies including
chemotherapy and I-131MIBG therapy.
5. Monotherapy with I-131 MIBG
Since the fi st I-131 MIBG therapy for neuroblastoma were
reported in 1986 [11], many monotherapy trials with I-
131 MIBG for refractory or relapsed neuroblastoma were
reported and obtained objective responses (partial or com-
plete response) in 0 to 66% [27, 28, 34–42]. In a report
from Germany, the objective response rate was 66% in 12
evaluable patients with refractory or relapsed neuroblastoma
with a mean dose of 10.3 mCi/kg of I-131 MIBG per each
therapy [37]. Compared with higher doses of I-131 MIBG,
lower doses tend to achieve lower objective responses. For
instance, an Italian group treated 42 patients with refractory
or relapsed neuroblastoma with 75 to 162 mCi of I-131MIBG
per each therapy [39]. The objective response rate was 16.7%.
Five of 7 patients with objective responses survived more
than 2 years without further chemotherapy. In the phase
II study by a French group, 26 patients with refractory or
relapsed neuroblastoma were treated with 30 to 108 mCi of
I-131 MIBG per each therapy [34]. Th ugh pain reduction
was seen in 50% of patients, no patients had any objective
response. In a recent report from Israel, I-131 MIBG therapy
at a dose of 5 mCi/kg (maximum dose 150 mCi) per each
therapy acquired pain palliation in 90% of the first therapies
and 87.5% of the second therapies in 10 symptomatic patients
with refractory neuroblastoma [43]. Lower doses of I-131
MIBG obtain a few objective responses, whereas can achieve
high-probability pain reduction (Figure 1).
In a phase I study from UCSF, 30 patients with refractory
or relapsed neuroblastoma were treated with I-131 MIBG at
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escalating doses of 3 to 18 mCi/kg per each therapy [28]. Th
objective response rate was 37%. Most patients with objective
responses were treated with 12mCi or higher of I-131MIBG.
A phase II study from a USA group reported some
predictive factors affecting the therapeutic response of I-
131 MIBG therapy in patients with refractory or relapsed
neuroblastoma [27]. Sixteen patients without hematopoietic
cell support were treated with 12mCi/kg I-131MIBG and 148
patients with hematopoietic cell support were treated with
18 mCi/kg I-131 MIBG. Th overall objective response rates
were 25% in patients treated with a dose of 12 mCi/kg and
37% in patients treated with a dose of 18 mCi/kg.The response
rate was signific ntly higher in patients with fewer prior
treatments, longer time from diagnosis, disease existed at soft
tissue only or bone and bone marrow only and older age. Th
one-year event-free survival (EFS) and overall survival (OS)
were 18% and 49%. Th two-year OS was 29%. The EFS was
signific ntly longer in patients with fewer prior treatments
and older age.
6. Tandem Therapy with I-131 MIBG
Many of studies with I-131 MIBG monotherapy included
patients with repetitive I-131 MIBG administrations. Each I-
131MIBG therapy was usually performed at intervals of more
than 2 or 3 months because of the problems of hematologic
toxicity and radiation safety.
The NANT consortium treated high-risk neuroblastoma
with tandem I-131 MIBG administrations 14 days apart
abrogating hematologic toxicity with autologous HCT (auto-
HCT) 2 weeks after the second I-131 MIBG therapy [30].
In this dose escalation study, 20 evaluable patients received
cumulative doses from 22 to 50 mCi/kg. All evaluable patients
engrafted after auto-HCT and had no dose-limiting toxicity.
Five of 11patients (45.5%) with soft tissue lesions had good
response. In contrast, bone marrow responses were seen
in only 2 of 13 patients (15.4%). In the Children’s Hospital
of Philadelphia, 41 patients received repetitive I-131 MIBG
therapies with auto-HCT at each dose of 18 mCi/kg [44]. Th
intervals of each therapy ranged from 42 to 100 days. Th
objective response rate after two therapies was 39%.
Th ugh tandem therapy of I-131 MIBG with HCT is
feasible, further studies are needed to improve therapeutic
responses.
7. I-131 MIBG Therapy Combined with
Chemotherapy
On the basis of I-131 MIBG monotherapeutic results, some
groups tried the combination therapy with I-131 MIBG
and chemotherapy agents act as radiosensitizers for refrac-
tory or relapsed neuroblastoma. In a report from Italy, 4
patients with refractory or relapsed neuroblastoma were
administered I-131MIBG in combination with cisplatin [45].
Two complete responses (CRs) and one partial response
(PR) were observed. In addition, the same group treated
16 patients with 200 mCi I-131 MIBG plus cisplatin and
cyclophosphamide with or without etoposide and vincristine
[46]. The objective response rate was 75%. The only toxicity
was hematological mainly associated with chemotherapy.
Regardless of relatively low dose of I-131MIBG, these results
were superior to the reports in monotherapy trials. A group
of the United Kingdom investigated the feasibility of the
combination therapy with I-131 MIBG and topoisomerase I
inhibitor, topotecan [47]. Eight patients were treated with
12 mCi I-131 MIBG on days 1 and 15 along with topotecan
on days 1–5 and 15–19. All patients received auto-HCT on
days 25–27. Th combination therapy was feasible without
unanticipated toxicities. Th response data was not shown in
the study. In a phase I study from the NANT consortium,
24 patients with refractory or relapsed neuroblastoma treated
with irinotecan which is another topoisomerase I inhibitor,
vincristine, and I-131 MIBG at escalating doses of 8 to
18 mCi/kg [48]. Th combination therapy was well tolerated at
the maximum dose of 18 mCi with controllable toxicities and
then a phase II randomized study by the NANT consortium is
now in progress (N2011-01).Vorinostat, a histone deacetylase
inhibitor, was preclinically proved to increase expression
of NE transporters in neuroblastoma cells [49]. A phase I
study with a combination of I-131 MIBG and vorinostat for
refractory or relapsed neuroblastoma is now examined by the
NANT consortium (N2007-03).
Myeloablative chemotherapy with auto-HCT was dem-
onstrated to improve the outcome in patients with high-
risk neuroblastoma [50]. Several groups reported I-131MIBG
therapy incorporated in myeloablative chemotherapy. A pilot
study from the University of Michigan examined the fea-
sibility and effic y of the combination therapy with I-131
MIBG and myeloablative chemotherapy in 12 patients with
relapsed or advanced neuroblastoma [51]. All patients were
treated with 12 mCi I-131 MIBG on day –21, followed by
carboplatin, etoposide, and melphalan (CEM) administered
on day –7 to day –4. Auto-HCT was performed on day 0.
Thi regimen was well tolerated. In evaluated 8 patients, 3
CRs and 2 PRs were observed. In a phase I dose escalation
study by the NANT consortium, 24 patients with refractory
neuroblastoma were treated with I-131 MIBG at escalating
doses of 12 to 18 mCi/kg on day –21 along with CEM on
day –7 to day –4 [29]. Th maximum tolerated dose of
I-131MIBG was 12mCi/kg when received in combination of
CEM in patients with normal renal function. In evaluable 22
patients, one CR and 5 PRs were observed. Th estimated
EFS and OS at 3 years were 0.31 ± 0.10 and 0.58 ± 0.10. A
phase II study by the Children’s Hospital Los Angeles using
I-131 MIBG combined with CEM and auto-HCT is recently
completed. Th other myeloablative chemotherapy regimen
using busulfan and melphalan (BuMel) with I-131 MIBG
was reported form a UCSF group [52]. Eight patients with
refractory neuroblastoma were treated with 18 mCi/kg I-131
MIBG on day –13 and auto-HCT on day 0. Six to eight weeks
after I-131 MIBG administrations, they received busulfan on
day –6 to day –2 and melphalan on day –1 and auto-HCT
on day 0. I-131 MIBG therapies at doses of 18 mCi/kg were
well tolerated without grade 3 or 4 nonhematologic toxicity
except for one patient with sepsis. Th ugh one patient died
due to respiratory complications after the second auto-HCT,
3 CRs, and 2 PRs were observed in evaluable 7 patients. I-131
Th Scientifi World Journal 5
Figur e 2: A 10-year-old male with relapsed neuroblastoma. He was
treated with 16.8 mCi/kg I-131 MIBG. Multiple lymph nodes and
bone metastases are detected by I-131 MIBG scintigraphy (arrows).
Afte the treatment with chemotherapy and whole-body irradiation,
he received CBSCT 4 weeks after the I-131MIBG therapy. Complete
remission has been maintained for more than 12 months.
MIBG therapy with myeloablative chemotherapy followed by
auto-HCT may provide additional benefit for patients with
refractory or relapsed neuroblastoma. Several further studies
are now ongoing.
8. I-131 MIBG Therapy and Allogeneic Stem
Cell Transplantation
Allogeneic HCT (allo-HCT) has been regarded as an alterna-
tive procedure for advanced neuroblastoma when autologous
stem cells could not be obtained suffici tly [53, 54]. Some
studies have recently reported the possibility to induce a
graft-versus-tumor (GVT) effect against advanced neurob-
lastoma [55–57]. Two patients with relapsed neuroblastoma
treated with I-131MIBG and allo-HCT were reported in case
reports from Japan [58, 59]. A 6-year-old female with relapsed
neuroblastoma received reduced-intensity allo-HCT 21 days
after I-131 MIBG therapy [59]. Th ugh no GVT effect was
observed, the patient was in CR for 3 months after allo-
HCT. A 5-year-old female with relapsed neuroblastoma was
executed cord blood stem cell transplantation (CBSCT) 9
days after I-131 MIBG therapy and GVT effect was observed
aft r CBSCT [58]. Normalization of both vanillylmandelic
acid and homovanillic acid for 5 months and decrease of
I-123 MIBG accumulations were maintained, although the
patient died 12 months after CBSCT. A 10-year-old male with
relapsed neuroblastoma received I-131 MIBG therapy and
CBSCT. Then, he got in remission for more than 12 months
aft r the therapy (Figure 2). Th ugh these reports indicate
the potency of the combination therapy with I-131MIBG and
allo-HCT, prospective trials combining I-131MIBG with allo-
HCT will be required.
9. I-131 MIBG Therapy Combined with
Hyperbaric Oxygen
Exposure of the neuroblastoma cells to hyperbaric oxygen
(HBO) enhanced the effects of I-131 MIBG on decreasing
cell proliferation and energy metabolism and increasing lipid
peroxidation [60]. The e effects may provide the positive
effects on neuroblastoma patients treated with the combi-
nation of I-131 MIBG and HBO. A Dutch group treated 36
neuroblastoma patients with I-131 MIBG therapy alone and
27 neuroblastoma patients with a combination of I-131MIBG
therapy and 4 to 5 days HBO therapy starting 2 days after
I-131 MIBG administrations [61]. The overall survival at 28
months was 32% for the I-131 MIBG and HBO combined
group, compared to 12% for the group of I-131MIBG therapy
alone. Th ugh only a few reports about the combination of
I-131 MIBG and HBO therapy were shown, adding on HBO
therapy may improve the effect of I-131MIBG therapy.
10. I-131 MIBG Therapy for Newly Diagnosed
Neuroblastoma
Based on the experience of I-131 MIBG therapy for refrac-
tory and relapsed neuroblastoma, several groups progressed
to the new stage in evaluating the utility of I-131 MIBG
therapy incorporated in the treatment for newly diagnosed
neuroblastoma. A Dutch group used I-131 MIBG as an up-
front agent of the induction therapy in patients with newly
diagnosed stage IV neuroblastoma [62]. Two cycles of I-
131 MIBG with a fi ed dose of 200 mCi and 100 mCi were
administered 4 to 6 weeks apart, followed by surgery or by
both neoadjuvant chemotherapy and surgery. If objective
responses were obtained after 2 cycles of I-131 MIBG ther-
apy, patients proceeded to surgery. Some of them received
additional I-131MIBG therapies until surgery. If the objective
responses were not obtained, patients were switched to induc-
tion chemotherapy until surgery. After surgery, all patients
received myeloablative chemotherapy plus auto-HCT. Of the
evaluable 41 patients, the objective response rate was 66%
after two cycles of I-131 MIBG therapy. In addition, bone
marrow metastases disappeared in 58%. Twenty-four patients
received only I-131 MIBG and surgery. In the 24 patients, 14
patients had a CR after only I-131MIBG plus surgery. The 5-
year OS for all evaluated 41 patients was 14.6%. I-131 MIBG
as an up-front use may be valuable for newly diagnosed
advanced neuroblastoma.
In a German Neuroblastoma Trial (NB97), a benefit
of I-131 MIBG therapy at the end of induction therapy in
neuroblastoma patients with residual disease was investigated
[63]. After induction therapy for newly diagnosed patients,
36 patients received I-131 MIBG therapy before auto-HCT
and 30 patients did not receive I-131 MIBG therapy before
auto-HCT. The 3-year EFS with or without I-131 MIBG
therapy was 49% and 33%. Th difference was not statistically
signific nt; however these results might indicate the additive
value of I-131 MIBG therapy after induction therapy in
patients with newly diagnosed neuroblastoma. Th following
trial (NB2004) is now in progress.
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An Italian group integrated I-131 MIBG therapy into
induction chemotherapy in 13 patients with newly diagnosed
advanced neuroblastoma [64]. In the pilot study, one CR and
6 very good PRs and 4 PRs were observed. These results
support the feasibility of I-131 MIBG therapy as a part of
induction therapy regimen. A pilot study of intensive induc-
tion chemotherapy and I-131 MIBG undergoing HCT for
newly diagnosed advanced neuroblastoma by the Children’s
Oncology Group is currently recruiting participants.
Recently, a Dutch group reported the result of I-131MIBG
therapy in patients with unresectable localized neuroblas-
toma [65]. Twenty-one patients with any organ dysfunctions
were treated with I-131 MIBG for unresectable localized
neuroblastoma. Most patients needed additional surgery or
both surgery and chemotherapy before or after I-131 MIBG
therapy. As a result, 16 CRs, 3 very good PRs, and one PR
were achieved. The 10-year EFS and OS were both 90.5%.
I-131 MIBG therapy for unresectable localized neuroblas-
toma might be considerable when patients have any organ
dysfunctions. To establish the validity and the utility of I-
131MIBG therapy for unresectable localized neuroblastoma,
further studies are needed.
11. Other Radiopharmaceuticals in
Connection with MIBG
I-131 MIBG is generally synthesized from iodine-127 MIBG
by replacing stable iodine with radioiodine. Consequently,
I-131 MIBG by the standard synthesis contains 1 radiola-
beled I-131MIBG molecule for 2000 nonradiolabeled MIBG
molecules [66]. Nonradiolabeled MIBG competes against
radiolabeled I-131 MIBG for NE transporter uptake on the
cell membranes of neuroblastoma and other target organs.
Some groups have synthesized no-carrier-added (NCA) I-
131MIBG and demonstrated the enhanced NCA I-131MIBG
concentrations within targets in preclinical studies [67, 68].
A phase I study about NCA I-131 MIBG showed safety in a
dose escalation from 6 to 8 mCi/kg in patients with malignant
pheochromocytoma or metastatic carcinoid [69]. In a phase
II study by the NANT consortium, 15 patients with refractory
or relapsed neuroblastoma received NCA I-131MIBG therapy
at escalation doses of 8.8 to 18.7 mCi/kg with stem cell backup
[70]. Dose-limiting toxicity was not observed in all of 3, 3, and
6 patients treated with 12,15, and 18 mCi/kg I-131MIBG. Th
objective response rate was 27%, including 1 CR. NCA I-131
MIBG therapy with HCT at a dose of 18 mCi/kg is feasible
without signific nt nonhematologic toxicity.
Because of the relatively long beta range of I-131(0.8 mm),
there is a hypothesis that I-131 fails to deliver a tumoricidal
radiation dose to a small tumor less than 1mm [71, 72].
Iodine-125 (I-125) emits very short-range Auger and con-
version electrons with a high linear energy transfer and the
maximum range of its emitters is about 30 𝜇m [73, 74].
The efore, I-125 MIBG has been considered as a potential
substitute for I-131MIBG for the treatment of neuroblastoma
with microscopic disease [72, 75, 76]. In phases I and II trials
by the University of Michigan, 10 patients with refractory
or relapsed neuroblastoma received I-125 MIBG therapy at
a dose of 224 to 814 mCi [75]. Th 1-year EFS was 50% and
4 patients were surviving 17 to 52 months after I-125 MIBG
therapy. Further studies are needed, such as for macroscopic
disease with a combination with I-125 MIBG and I-131MIBG
and for microscopic disease with I-125 MIBG.
Astatine-211(At-211)generates alpha particles which are
radiations of high linear energy transfer (LET) with very
short-range in tissue of only a few cell diameters [77]. Because
of shorter path length, higher LET, and more potent cytotox-
icity, alpha particles are more suitable than beta particles for
the targeted radionuclide therapy for microscopic disease. In
a clinical experience, At-211-labeled antitenascin monoclonal
antibodies were regionally administered in patients with
malignant brain tumors [78]. This pilot study demonstrated
the regional administration of At-211-labeled antitenascin
antibody was feasible, safe, and effective for malignant brain
tumors. MIBG analogue labeled with At-211,At-211meta-
astatobenzylguanidine (MABG) was proved to have a cyto-
toxic superiority to I-131MIBG in human nuroblastoma cells
which overexpressed NE transporters [79–81]. Alpha emitters
hold enormous potentialities for radionuclide therapy. Fur-
ther studies about At-211MABG and other alpha emitters in
both preclinical and clinical settings will be desired and will
lead to future development of radionuclide therapy.
12. Conclusions
A number of studies indicate the effic y of I-131MIBG ther-
apy in patients with refractory or relapsed neuroblastoma. In
addition, I-131 MIBG therapy incorporated in the induction
therapy is the feasible treatment strategy in patients with
newly diagnosed neuroblastoma. To more expand the use
of MIBG therapy for neuroblastoma, further studies will be
needed especially in the use at an earlier date from diagnosis,
in the use with other radionuclide formations of MIBG and
in combined use with other therapeutic agents.
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